ID - 821
DARATUMUMAB + BORTEZOMIB, LENALIDOMIDE, AND DEXAMETHASONE (DVRD) VS VRD IN TRANSPLANT-INELIGIBLE (TIE)/TRANSPLANT-DEFERRED (TD) NEWLY DIAGNOSED MULTIPLE MYELOMA (NDMM): PHASE 3 CEPHEUS TRIAL CYTOGENETIC SUBGROUP ANALYSIS
NJ Bahlisa, SZ Usmanib, T Faconc, S Zweegmand, C Vennere, M Braunsteinf, L Pourg, J Martih, A Maiolinoi, V Hungriaj
a Arnie Charbonneau Cancer Research Institute, University of Calgary, Calgary, Canada
b Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, United States
c University of Lille, CHU Lille, Lille,France
d Amsterdam University Medical Center, Vrije Universiteit Amsterdam, Amsterdam, Netherlands
e Cross Cancer Institute, University of Alberta, Edmonton, Canada
f Perlmutter Cancer Center, NYU Langone Health, New York, United States
g University Hospital Brno, Brno, Czech Republic
h Hospital Universitario Mútua de Terrassa, Terrassa, Spain
i Instituto Americas de Ensino, Pesquisa e Inovação, Rio de Janeiro, Brazil
j Clínica Médica São Germano, São Paulo, Brazil
Ver más
